






#### Laura Cantini


**Computational Systems Biology Team IBENS**, Paris

## Personalized cancer medicine

Patients with same cancer type don't have the same survival, treatment response and molecular characteristics




## Personalized cancer medicine



Classify cancer patients into groups with similar prognosis, drug response or molecular features

## Multi-omics data available




**Environmental Exposures** 

## **The Cancer Genome Atlas (TCGA)** for example contains data from 10.000 patients, 33 cancer types, 6 omics, plus clinical data


The Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.M., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J.M. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. doi:10.1038/ng.2764

Sun, Yan V., and Yi-Juan Hu. "Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases." Advances in genetics. Vol. 93. Academic Press, 2016. 147-190.




The Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.M., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J.M. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. doi:10.1038/ng.2764

Sun, Yan V., and Yi-Juan Hu. "Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases." Advances in genetics. Vol. 93. Academic Press, 2016. 147-190.




The Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.M., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J.M. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. doi:10.1038/ng.2764

Sun, Yan V., and Yi-Juan Hu. "Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases." Advances in genetics. Vol. 93. Academic Press, 2016. 147-190.



The Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.M., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J.M. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. doi:10.1038/ng.2764 Sun, Yan V., and Yi-Juan Hu. "Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases." *Advances in genetics*. Vol. 93. Academic Press, 2016. 147-

Sun, Yan V., and YI-Juan Hu. Integrative analysis of multi-omics data for discovery and functional studies of complex numan diseases. Advances in genetics. Vol. 93. Academic PI 190.



#### The joint analysis of multiple omics is required

The Cancer Genome Atlas Research Network, Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.M., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., and Stuart, J.M. (2013) The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. doi:10.1038/ng.2764 Sun, Yan V., and Yi-Juan Hu. "Integrative analysis of multi-omics data for discovery and functional studies of complex human diseases." *Advances in genetics*. Vol. 93. Academic Press, 2016. 147-190.

#### **Challenges of multi-omics integration**

High-dimensionality -> Big-data

Heterogeneous variables

Different ranges of variation

Technical noise different for each omics

# More omics is better, but how many more?



# Is it always good to consider ALL the available omics?



Aim: predicting drug response


#### Available input data:

- Mutations
- Copy Number Alterations (CNA)
- Methylation
- Gene expression
- Proteomics
- Cancer types
- Drug response


Aim: predicting drug response


#### Available input data:

- Mutations
- Copy Number Alterations (CNA)
- Methylation
- Gene expression
- Proteomics
- Cancer types
- Drug response



#### Using correlation:






Aim: predicting drug response


#### Available input data:


- Mutations
- Copy Number Alterations (CNA)
- Methylation
- Gene expression
- Proteomics
- Cancer types
- Drug response




#### Using partial correlation (iTOP):








ABEN, Nanne, et al. iTOP: inferring the topology of omics data. Bioinformatics, 2018, 34.17: i988-i996.



ABEN, Nanne, et al. iTOP: inferring the topology of omics data. Bioinformatics, 2018, 34.17: i988-i996.




ABEN, Nanne, et al. iTOP: inferring the topology of omics data. Bioinformatics, 2018, 34.17: i988-i996.

# How the omics should be combined?

#### Approach "Genome First"

Priority given to genome

Other omics are only used for interpretation









Machine learning algorithm designed for a single dataset




#### Late integration

output averaging, ensembles









# Main categories of existing multi-omics integrative approaches

# Main categories of integrative approaches

#### Supervised methods




#### Unsupervised methods



# Main categories of integrative approaches

#### Supervised methods




- They require 2 datasets in input: training and test datasets
- Labels must be avilable for the training dataset
- This information is used to infer labels on the test dataset


# Main categories of integrative approaches


#### Unsupervised methods

- The methodology is directly applied to one dataset
- They infer information from the structure of the data without any label information











#### Unsupervised data integration




Unsupervised data integration





# Cancer insights from data integration methods

#### **Cancer subtyping**





CMS1 (13%)	CM52 (35%)	CM53 (11%)	CMS4 (20%)	Unclassified (21%)
<ul> <li>Right colon, female</li> <li>MSI, BRAF mut, hypermutated</li> <li>Immune activation</li> <li>Worse survival after relapse</li> </ul>	<ul> <li>Left colon</li> <li>MSS, CIN, BRAF wt, TP53 mut</li> <li>Epithelial, WNT/Myc pathway activation</li> <li>Better survival after relapse</li> </ul>	KRAS mut     Epithelial, IGFBP2     overexpression	<ul> <li>Mesenchymal, TGFβ pathway activation, NOTCH3 overexpression</li> <li>Worse relapse free survival and overall survival</li> </ul>	<ul> <li>Immune and stroma infiltration</li> <li>Variable epithelial - mesenchymal activation</li> </ul>
C2 Subtype 1.2 A-type CCS2 Inflammatory	C1-C5-C6 Subtype 2.2 B CCS1 Enterocyte-TA	C3 Subtype 2.1 Globet-like A	C4 C-type Subtype 1.1-1.3 CCS3 D-E Stem-like	

Santos, Cristina, et al. "Intrinsic cancer subtypes-next steps into personalized medicine." Cellular oncology 38.1 (2015): 3-16.

#### **Cancer subtyping**

This problem is generally approached with unsupervised approaches.






#### Gene modules identification



Which are the molecular mechanisms that make these two groups of patients having a different behaviour?


Can we identify a driver that can alter the behaviour of a set of patients?

#### Gene modules identification




# **Matrix Factorization**

## Joint Dimensionality Reduction (jDR)




## Joint Dimensionality Reduction (jDR)

Multi-omics joint Dimensionality Reduction (jDR)




### Multi-omics Factor Analysis (MOFA)




Argelaguet, Ricard, et al. "Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets." Molecular systems biology 14.6 (2018): e8124.

## **MOFA** advantage: interpretability of factors




Variance decomposition by factor




### Annotation of factors


Inspection of loadings Feature set enrichment analysis



#### Imputation of missing values


#### Inspection of factors





Argelaguet, Ricard, et al. "Multi-Omics Factor Analysis-a framework for unsupervised integration of multi-omics data sets." Molecular systems biology 14.6 (2018): e8124.

Also single-cell multi-omics data can be integrated with matrix factorization



Hu, Youjin, et al. " Frontiers in cell and developmental biology 6 (2018): 28.

# Example MOFA application single-cell multi-omics


Dataset: 87 mouse embryonic stem cells (mESCs) comprising:

- 16 cells cultured in "2i" media, which induces a naive pluripotency state
- 71 serum-grown cells, which commits cells to a primed pluripotency state poised for cellular differentiation.

All cells were profiled using single-cell methylation and transcriptome sequencing

Argelaguet, Ricard, et al. "Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets." Molecular systems biology 14.6 (2018): e8124.


# Example MOFA application single-cell multi-omics



Argelaguet, Ricard, et al. "Multi-Omics Factor Analysis—a framework for unsupervised integration of multi-omics data sets." Molecular systems biology 14.6 (2018): e8124.


# Linked inference of genomic experimental relationships (LIGER)

### Integrative Non Negative Matrix Factorization (iNMF)



### $E_i = H_i V_i + H_i W$

## LIGER: multi-omics clustering




# LIGER: peripheral blood mononuclear cell (PBMC)


scRNAseq and scATACseq data from approx. 10k cells PBMCs

We want to identify subtypes of cells based on the joint analysis of the two data types

# LIGER: peripheral blood mononuclear cell (PBMC)



## Pay attention this is not a TSNE plot of scRNAseq data



## LIGER: peripheral blood mononuclear cell (PBMC)

